
DiaMedica Therapeutics Inc.
100
Recent developments include multiple earnings call transcripts and highlights for Q1 and Q2 2026, analyst commentary on potential stock movement, and updates on clinical trial progress and regulatory interactions.
- DiaMedica reported Q2 2026 earnings with detailed call transcripts and highlights discussing clinical trial progress and financial results [N2][N3].
- The company continues enrollment and site activation for the ReMEDy2 Phase 2/3 trial in acute ischemic stroke [N2][N3].
- Health Canada approved initiation of a Phase 2 trial in early-onset preeclampsia in North America and the UK, with plans to expand trial sites [S1][N3].
- Interim Phase 2 results in preeclampsia showed DM199 was safe, well-tolerated, and reduced blood pressure significantly [S1][N3].
- Analysts have published commentary on DiaMedica's potential stock movement based on clinical and financial developments [N1].
- The company entered oversold territory in April 2026, reflecting market volatility [N7].
- Financial results for Q1 and Q4 2025 were also released with earnings call transcripts available [N4][N5][N6].
DiaMedica Therapeutics Inc. focuses on developing recombinant human kallikrein-1 (KLK1) protein therapies for ischemic diseases. Its lead candidate, DM199, is designed to improve endothelial function and blood flow by activating the kallikrein-kinin system, which enhances production of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor. The company targets preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS). Clinical programs include a Phase 2 investigator-sponsored trial in PE in South Africa, a planned global Phase 2 trial in early-onset PE in North America and the UK, and an ongoing Phase 2/3 adaptive trial for AIS. DM199 has received FDA Fast Track Designation for AIS. The company is also developing DM300, a recombinant human ulinastatin, for severe acute pancreatitis. DiaMedica's strategy includes advancing clinical trials, manufacturing process development, and seeking strategic partnerships for commercialization [S1].
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing DM199, a recombinant human kallikrein-1 protein, targeting severe ischemic diseases including preeclampsia, fetal growth restriction, and acute ischemic stroke. The company is advancing multiple clinical trials, including a Phase 2 investigator-sponsored trial in preeclampsia and a Phase 2/3 adaptive trial in acute ischemic stroke. Financially, as of September 30, 2026, DiaMedica held $6.8 million in cash and $28.1 million in short-term investments, with a strong liquidity position (current ratio 4.76). The company reported a net loss of $31.5 million for the nine months ended September 30, 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
The bull case for DiaMedica centers on successful clinical development and regulatory approvals of DM199 for preeclampsia and acute ischemic stroke, addressing significant unmet medical needs with no current FDA-approved therapies for PE. Positive clinical trial results demonstrating safety and efficacy could validate the recombinant KLK1 approach, potentially leading to commercial adoption. The company's strong liquidity position supports ongoing development activities. Strategic partnerships could accelerate commercialization and broaden market reach. The large patient populations affected by PE, FGR, and AIS represent substantial market opportunities [S1][N1].
The bear case involves clinical trial risks including delays, negative or inconclusive results, and regulatory hurdles such as the FDA's request for additional non-clinical studies which have encountered challenges. The company operates in a competitive and rapidly evolving environment with inherent uncertainties. Financial losses and cash burn may require additional capital raising, potentially diluting shareholders. The recombinant KLK1 approach, while promising, has yet to achieve regulatory approval anywhere globally, and market acceptance remains uncertain. Manufacturing and commercialization risks also exist [S1][S2].
DiaMedica's moat lies in its proprietary recombinant human kallikrein-1 (rhKLK1) protein, DM199, which is the first pharmaceutically active recombinant form of KLK1 in clinical development. Existing KLK1 therapies in Asia are derived from human urine or pig pancreas, with limitations related to regulatory standards and impurities. DM199 aims to overcome these drawbacks by providing a recombinant, consistent, and potentially safer alternative. The company's clinical-stage status with FDA Fast Track Designation for AIS and ongoing trials in PE and AIS provide regulatory and clinical development barriers to entry. The extensive scientific and clinical data supporting KLK1's role in vascular health and ischemic diseases further underpin the company's competitive position [S1].
• Clinical Development Risk: Ongoing clinical trials may face delays, fail to demonstrate safety or efficacy, or encounter regulatory challenges, including the FDA's request for additional animal studies which have been difficult to complete.
• Regulatory Risk: Approval processes are complex and may require additional data or studies, potentially delaying or preventing market authorization.
• Financial Risk: The company has reported net losses and relies on capital to fund operations; insufficient funding could impact development progress.
• Market and Commercialization Risk: Even if approved, DM199 may face challenges in market adoption, competition, and manufacturing scale-up.
Business trends: Advancement of recombinant KLK1 therapy DM199 in clinical trials for preeclampsia and acute ischemic stroke, with regulatory interactions and expanding trial sites.
Execution milestones: Completion of Phase 2 investigator-sponsored trial parts, initiation of global Phase 2 PE trial, ongoing adaptive Phase 2/3 AIS trial enrollment, and manufacturing process development.
Key risks: Clinical trial outcomes and regulatory approvals remain uncertain; additional non-clinical studies requested by FDA pose potential delays; financial sustainability depends on capital availability and successful development.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on severe ischemic diseases, primarily preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS) [S1].
- The lead drug candidate is DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein-1 (rhKLK1) protein, which has FDA Fast Track Designation for AIS treatment [S1].
- DM199 is the first pharmaceutically active recombinant form of KLK1 studied clinically; KLK1 derived from human urine and pig pancreas is used in Asia for AIS and cardio-renal diseases [S1].
- The company is conducting a Phase 2 investigator-sponsored trial (IST) in PE patients at Tygerberg Hospital, South Africa, with multiple parts including dose-escalation and dose-expansion cohorts [S1].
- Interim results from Part 1a (28 subjects) showed DM199 is safe, well-tolerated, with pharmacodynamic activity including rapid, statistically significant blood pressure reductions sustained up to 24 hours post-infusion [S1].
- An extension cohort is enrolling approximately 10 subjects at therapeutic dose levels; preparations are underway for Part 1b with up to 30 PE subjects [S1].
- A global Phase 2 trial in early-onset PE is planned for North America and the UK; Health Canada approved initiation and UK trial application is anticipated [S1].
- FDA requested an additional non-clinical embryo-fetal development study in rabbits; preliminary results showed antibody response preventing completion; alternative animal models are being evaluated [S1].
- The ReMEDy2 Phase 2/3 trial for AIS is ongoing, adaptive design, randomized, double-blind, placebo-controlled, targeting up to 728 patients globally with interim analysis after 200 patients [S1].
- DM199 aims to improve endothelial health, microcirculatory blood flow, and tissue perfusion by increasing nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor production [S1].
- KLK1 levels are reduced in PE and stroke patients; augmentation with DM199 is intended to restore vascular function and improve outcomes [S1].
- No FDA-approved therapies currently exist for PE; current treatments manage symptoms but do not modify disease progression [S1].
- Financial snapshot as of 2026-09-30: cash and equivalents $6.8M, short-term investments $28.1M, current assets $35.5M, current liabilities $7.45M, current ratio 4.76, cash ratio 4.68 [S2].
- Net loss for nine months ended 2026-09-30 was $31.5M; basic net loss per share was $0.58 [S2].
- Research and development expenses for the nine months ended 2026-09-30 were $25.4M; general and administrative expenses were $7.2M [S2].
- The company has approximately 54 million shares outstanding as of 2026-09-30 [S2].
- Recent news includes multiple earnings call transcripts and highlights for Q1 and Q2 2026, and analyst commentary on potential stock movement [N1][N2][N3][N4][N5][N6][N7][N8].
Generated 2026-11-13
- N2
- N3
- N4
- N5
- N6
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-08-26 | www.nasdaq.com | Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet | https://www.nasdaq.com/articles/wall-street-analysts-think-diamedica-therapeutics-dmac-could-surge-12997-read-placing-bet
- N2 | 2026-08-18 | www.nasdaq.com | DiaMedica (DMAC) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/diamedica-dmac-q2-2026-earnings-call-transcript
- N3 | 2026-08-11 | www.nasdaq.com | DiaMedica Therapeutics Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/diamedica-therapeutics-q2-earnings-call-highlights
- N4 | 2026-06-01 | www.nasdaq.com | DiaMedica (DMAC) Q4 2025 Earnings Transcript | https://www.nasdaq.com/articles/diamedica-dmac-q4-2025-earnings-transcript
- N5 | 2026-05-08 | www.nasdaq.com | DiaMedica (DMAC) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/diamedica-dmac-q1-2026-earnings-transcript
- N6 | 2026-05-07 | www.nasdaq.com | DiaMedica Therapeutics Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/diamedica-therapeutics-q1-earnings-call-highlights
- N7 | 2026-04-08 | www.nasdaq.com | DiaMedica Therapeutics Enters Oversold Territory (DMAC) | https://www.nasdaq.com/articles/diamedica-therapeutics-enters-oversold-territory-dmac
- N8 | 2026-03-30 | www.nasdaq.com | After-Hours Earnings Report for March 30, 2026 : PRGS, PHR, DMAC, AIRJ, SPCE, HQI, SGMO, RNXT, INLX, FTHM | https://www.nasdaq.com/articles/after-hours-earnings-report-march-30-2026-prgs-phr-dmac-airj-spce-hqi-sgmo-rnxt-inlx-fthm
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


